HK1244227A1 - 長效生長激素劑型 - Google Patents

長效生長激素劑型

Info

Publication number
HK1244227A1
HK1244227A1 HK18103805.9A HK18103805A HK1244227A1 HK 1244227 A1 HK1244227 A1 HK 1244227A1 HK 18103805 A HK18103805 A HK 18103805A HK 1244227 A1 HK1244227 A1 HK 1244227A1
Authority
HK
Hong Kong
Prior art keywords
long
dosage forms
growth hormone
acting growth
hormone dosage
Prior art date
Application number
HK18103805.9A
Other languages
English (en)
Inventor
Kennett Sprogøe
Henrik Egesborg
Steen Jensen
Thomas Kurpiers
Original Assignee
Ascendis Pharma Endocrinology Div A/S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ascendis Pharma Endocrinology Div A/S filed Critical Ascendis Pharma Endocrinology Div A/S
Publication of HK1244227A1 publication Critical patent/HK1244227A1/zh

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/27Growth hormone [GH], i.e. somatotropin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61MDEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
    • A61M5/00Devices for bringing media into the body in a subcutaneous, intra-vascular or intramuscular way; Accessories therefor, e.g. filling or cleaning devices, arm-rests
    • A61M5/178Syringes
    • A61M5/19Syringes having more than one chamber, e.g. including a manifold coupling two parallelly aligned syringes through separate channels to a common discharge assembly
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/02Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dermatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Anesthesiology (AREA)
  • Biomedical Technology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
HK18103805.9A 2014-11-21 2018-03-19 長效生長激素劑型 HK1244227A1 (zh)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP14194248 2014-11-21
PCT/EP2015/077229 WO2016079302A1 (en) 2014-11-21 2015-11-20 Long-acting growth hormone dosage forms

Publications (1)

Publication Number Publication Date
HK1244227A1 true HK1244227A1 (zh) 2018-08-03

Family

ID=51945762

Family Applications (1)

Application Number Title Priority Date Filing Date
HK18103805.9A HK1244227A1 (zh) 2014-11-21 2018-03-19 長效生長激素劑型

Country Status (12)

Country Link
US (1) US20170312342A1 (zh)
EP (2) EP3988083A1 (zh)
CY (1) CY1124734T1 (zh)
DK (1) DK3220892T3 (zh)
ES (1) ES2896971T3 (zh)
HK (1) HK1244227A1 (zh)
HR (1) HRP20211734T8 (zh)
HU (1) HUE056849T2 (zh)
PL (1) PL3220892T3 (zh)
PT (1) PT3220892T (zh)
SI (1) SI3220892T1 (zh)
WO (1) WO2016079302A1 (zh)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018044060A1 (en) * 2016-08-30 2018-03-08 Genexine,Inc. PHARMACEUTICAL COMPOSITION FOR TREATING GROWTH HORMONE DEFICIENCY CONTAINING hGH FUSION PROTEIN
JOP20190019A1 (ar) * 2016-08-30 2019-02-12 Genexine Inc تركيبة صيدلانية لعلاج نقص في هرمون نمو يحتوي على بروتين اندماجي لهرمون نمو بشري (hGH)
SG11202108735QA (en) * 2019-03-04 2021-09-29 Ascendis Pharma Endocrinology Div A/S Long-acting growth hormone dosage forms with superior efficacy to daily somatropin
WO2022197963A1 (en) * 2021-03-19 2022-09-22 Pfizer Inc. Long-acting growth hormone compositions
IL305661A (en) * 2021-03-19 2023-11-01 Pfizer Methods of administration of polypeptides of growth hormones that have effects over time
CA3238895A1 (en) * 2021-11-26 2023-06-01 Genexine, Inc. High-concentration administration formulation of hgh fusion protein

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2539253A1 (en) 2003-09-19 2005-03-31 Novo Nordisk A/S Albumin-binding derivatives of therapeutic peptides
ES2741524T3 (es) 2004-03-23 2020-02-11 Ascendis Pharma Gmbh Profármaco polimérico con un enlazador autoinmolador
US8450269B2 (en) 2006-02-03 2013-05-28 Prolor Biotech Ltd. Long-acting growth hormone and methods of producing same
EP2369005B1 (en) 2007-06-21 2013-04-03 Technische Universität München Biological active proteins having increased in vivo and/or in vitro stability
SI3050576T1 (sl) 2008-04-29 2021-08-31 Ascendis Pharma Endocrinology Division A/S Spojine pegiliranega rekombinantnega humanega rastnega hormona
AU2010332958B2 (en) * 2009-12-15 2014-09-18 Ascendis Pharma Endocrinology Division A/S Dry growth hormone composition transiently linked to a polymer carrier
WO2011123813A2 (en) 2010-04-02 2011-10-06 Amunix Operating Inc. Binding fusion proteins, binding fusion protein-drug conjugates, xten-drug conjugates and methods of making and using same
EP2571510B1 (en) 2010-05-21 2018-08-08 XL-protein GmbH Biosynthetic proline/alanine random coil polypeptides and their uses
US20150250882A1 (en) 2012-10-17 2015-09-10 Novo Nordisk Health Care Ag Fatty Acid Acylated Amino Acids for Growth Hormone Delivery
KR102608645B1 (ko) * 2014-11-18 2023-12-01 아센디스 파마 엔도크리놀로지 디비전 에이/에스 신규한 중합체성 hGH 프로드러그

Also Published As

Publication number Publication date
US20170312342A1 (en) 2017-11-02
ES2896971T3 (es) 2022-02-28
SI3220892T1 (sl) 2022-01-31
DK3220892T3 (da) 2021-11-08
EP3988083A1 (en) 2022-04-27
WO2016079302A1 (en) 2016-05-26
HRP20211734T8 (hr) 2022-03-04
CY1124734T1 (el) 2022-07-22
EP3220892A1 (en) 2017-09-27
EP3220892B1 (en) 2021-10-13
HRP20211734T1 (hr) 2022-02-18
PT3220892T (pt) 2021-11-05
HUE056849T2 (hu) 2022-03-28
PL3220892T3 (pl) 2022-01-31

Similar Documents

Publication Publication Date Title
IL252708A0 (en) Immediate-release granulated dosage forms prevent abuse
GB201509443D0 (en) Seed preparation
GB201407896D0 (en) Insulin dosage proposal system
GB201416281D0 (en) Vegetation catergorisation
HK1244227A1 (zh) 長效生長激素劑型
SG11201702298VA (en) Pharmaceutical preparation
IL251413A0 (en) Composition of injectable buprenorphine
GB201612894D0 (en) Bird feeder
ZA201608085B (en) Grout delivery
TWI561461B (en) Epitaxial structure
HK1232184A1 (zh) 分批處理式的土壤改良
PL3143095T3 (pl) Mieszanina soli
TWM488998U (en) Syringe
PT2910223T (pt) Emplastro com dispensador de medicação
SG11201704819WA (en) Syringe
HRP20181406T1 (hr) Farmaceutski dozni oblici
IL255667A (en) Plant hormone application
GB201411038D0 (en) Bird feeder
GB2525899B (en) Bird Feeder
GB201413196D0 (en) Bale Spike
HU4548U (en) High flowerbed construction
GB201508787D0 (en) Pharmaceutically active compounds
TWM489981U (en) Warm-keeping structure
TWM489515U (en) Warm-keeping scarf structure
GB201415811D0 (en) Solid dosage form production